 SEATTLE--BUSINESS WIRE--Omeros Corporation Nasdaq: OMER, a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, immunologic diseases e.g., complement-mediated diseases and cancers and central nervous system disorders, today reported that the U.S. Food and Drug Administration FDA will require additional time to review the Biologics 